BG1430U1 - Фармацевтично средство - Google Patents
Фармацевтично средствоInfo
- Publication number
- BG1430U1 BG1430U1 BG1811U BG181110U BG1430U1 BG 1430 U1 BG1430 U1 BG 1430U1 BG 1811 U BG1811 U BG 1811U BG 181110 U BG181110 U BG 181110U BG 1430 U1 BG1430 U1 BG 1430U1
- Authority
- BG
- Bulgaria
- Prior art keywords
- pharmaceutical formulation
- hifn
- formulation
- pharmacopoeial
- stabilizers
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Полезният модел се отнася до фармацевтично средство за потискане действието на ендогенния човешки гама интерферон (hIFN-гама) при заболявания, свързани с абнормена продукция на hIFN-гама, пo-специално автоимунни заболявания и посттрансплантна артериосклероза. То представлява лиофилна форма за парентерално приложение, включваща рекомбинантен протеин, фармакопейни буфери и стабилизатори.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BG1811U BG1430U1 (bg) | 2010-06-25 | 2010-06-25 | Фармацевтично средство |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BG1811U BG1430U1 (bg) | 2010-06-25 | 2010-06-25 | Фармацевтично средство |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG1430U1 true BG1430U1 (bg) | 2011-04-29 |
Family
ID=45877018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG1811U BG1430U1 (bg) | 2010-06-25 | 2010-06-25 | Фармацевтично средство |
Country Status (1)
| Country | Link |
|---|---|
| BG (1) | BG1430U1 (bg) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US82138A (en) * | 1868-09-15 | Improvement in liquid-metees | ||
| WO1995030435A2 (en) * | 1994-05-10 | 1995-11-16 | Immulogic Pharmaceutical Corporation | Compositions and treatment for multiple sclerosis |
| CA2361081A1 (en) * | 1999-01-20 | 2000-07-27 | The University Of Queensland | Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis |
-
2010
- 2010-06-25 BG BG1811U patent/BG1430U1/bg unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US82138A (en) * | 1868-09-15 | Improvement in liquid-metees | ||
| WO1995030435A2 (en) * | 1994-05-10 | 1995-11-16 | Immulogic Pharmaceutical Corporation | Compositions and treatment for multiple sclerosis |
| CA2361081A1 (en) * | 1999-01-20 | 2000-07-27 | The University Of Queensland | Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX421064B (es) | Composiciones de nanoparticulas lipidicas y metodos para administracion de arnm | |
| EP4276180A3 (en) | Clostridium histolyticum enzyme | |
| NZ600709A (en) | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof | |
| CA2877521C (en) | Cells for producing recombinant iduronate-2-sulfatase | |
| NZ623294A (en) | Stabilized alpha-galactosidase and uses thereof | |
| WO2012047733A3 (en) | Treatment of acne by conditioned media | |
| NZ702801A (en) | Treatment of sanfilippo syndrome type b | |
| EP4218723A3 (en) | Long-acting formulations of insulins | |
| WO2012000103A8 (en) | Methods of targeting pten mutant diseases and compositions therefor | |
| EP4331620A3 (en) | Lipidic nanoparticles for mrna delivery | |
| NZ610556A (en) | Stem cell suspension | |
| MX2013002725A (es) | Metodo para atenuar los efectos adversos del farmaco usando los acidos grasos omega-3 como un vehiculo terapeutico parenteral del farmaco. | |
| NZ597580A (en) | Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof | |
| EP2558124A4 (en) | POLYSACCHARID COMPOSITIONS AND METHOD FOR USE THEREOF FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH PRECURSOR CELL MOBILIZATION | |
| WO2012115903A3 (en) | Yeast strain for the production of proteins with modified o-glycosylation | |
| BR112014021326A2 (pt) | célula para a expressão de protéina, método para reduzir a atividade de amidação de peptídeo em uma determinada célula, uso de uma célula | |
| MX392532B (es) | Glicoproteinas recombinantes y sus usos. | |
| IN2014DN05784A (bg) | ||
| BG1430U1 (bg) | Фармацевтично средство | |
| IN2014MN02461A (bg) | ||
| MX2012012489A (es) | Preparacion de polipeptidos y sales de los mismos. | |
| EP3065705A4 (en) | Compositions and methods for administration of an enzyme to a subject's airway | |
| WO2012129449A3 (en) | High level production of recombinant proteins | |
| IN2012CH03778A (bg) | ||
| WO2013023166A3 (en) | Hapivirins and diprovirins |